A financial analysis report of three typical biopharmaceutical companies in UK

Due to the impact of COVID-19 in recent years, more and more people are beginning to turn their attention to the development of pharmaceutical companies. In particular, some investors have shifted their investment targets to the pharmaceutical sector. In addition, they actively study the financial data and non-financial performance of companies in related fields in order to make reasonable investment decisions in line with investment expectations. At the same time, due to the impact of COVID-19, the business and performance of pharmaceutical companies have changed from the previous year. Therefore, this paper selects three typical UK pharmaceutical groups, AstraZeneca, Glaxo Smith Kline and Hikma Pharmaceuticals (Forbes, 2020)[16], to analyze their financial and non-financial performance in order to bring information users some usable information for investment.